News
New articles have been added to our file section.
Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths.
Vikas Prasad & Lisa Bodei & Mark Kidd & Irvin M. Modlin
90Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy.90Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy.
Samer Ezziddin, Carsten Meyer, Stanislawa Kahancova, Torjan Haslerud, Winfried Willinek, Kai Wilhelm, Hans-Jürgen Biersack, and Hojjat Ahmadzadehfar
More resource documents can be found in our file section.
As of January 2020, Dr. Baum will be located at the THERANOSTICS CENTER FOR RADIOMOLECULAR PRECISION ONCOLOGY in Wiesbaden (very close to Frankfurt/Main airport (20 minutes by car or commuter train)). Dr. Baum will have full access to complete diagnostic and treatment facilities.
As of December 15, 2019, please use the following contact information:
Professor Dr. Richard P. Baum, MD, PhD
THERANOSTICUM Frankfurt-Wiesbaden
at DKD Clinic
Aukammallee 33
65191 Wiesbaden, Germany
A committee of international experts under the auspices of the International Atomic Energy Agency (IAEA), in cooperation with the EANM Therapy, Oncology and Dosimetry Committees and with the Society of Nuclear Medicine and Molecular Imaging, worked together to create this guidance document on the use of somatostatin analogue-based PRRNT. This 120 page guidance document released in February 2013, was compiled taking into account recent literature and experts’ opinion and can be downloaded here
BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Click here to read the full release the Society of Nuclear Medicine and Molecular Imaging and from
Advanced Accelerator Applications (AAA) Receives European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine
AAA announced on September 29, 2017 that the European Commission (EC) has approved the marketing authorization of lutetium (177Lu) oxodotreotide* (Lutathera®) for “the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
1/26/18 - Advanced Accelerator Applications (AAA) Receives FDA Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine
AAA announced that the Federal Drug Administration (FDA) has approved the new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Click here to
For the third year, the Society of Nuclear Medicine and Molecular Imaging's Patient Advocacy Advisory Board developed a Patient Program to address key topics of interest to the patient and patient advocacy community. These presentations were given at the SNMMI Patient Education Day, June 9th in Vancouver, BC.